The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Microneedles for Trans / Intradermal Drug Delivery

  • Lowest Price Guaranteed From USD 1,899

  • Published
    October 2014

  • Pages
    210

  • View Count
    4958

Example Insights

  1. Microneedles can deliver a plethora of drugs and vaccines; the technology is not limited to any specific class of drugs. More than 70% of the products in development are patches incorporating solid or dissolvable needles, rest are hollow microneedle arrays which employ the use of a syringe.
  2. About 12 products based on microneedle technology are currently in clinical development, more than half of which are in phase II or a higher stage of development. In addition, there are a number of other products currently in preclinical trials.
  3. Amongst the various firms involved in developing microneedle products, almost 50% are start-ups, which have received financial support from various investors.
  4. Many academic institutions are also exploring the use of microneedles for diagnostics, gene delivery and continuous drug monitoring purposes. Majority of these research projects are focused in developing microneedle products as easy-to-use wearable patches.
  5. With several new microneedle based therapeutic product launches by the end of this decade, we expect the overall market for microneedle based delivery devices to reach annual sales of 485 million units by 2030.

Overview

Transdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.

The market is still in its infancy. So far, only one microneedle based delivery device, Soluvia prefilled microinjection system, has reached the market. The vaccine-device combination product was FDA approved in May 2011 for intradermal delivery of Fluzone influenza vaccine. We have identified more than 25 companies, with proprietary microneedle technology, actively working towards the development of microneedle-based drug or vaccine products. Clearside Biomedical, NanoPass Technologies, Corium International, Circassia, Radius Health and Zosano Pharma are examples of companies which are evaluating microneedle based drug/vaccine – device combination products (referred to as products hereafter) in clinical trials.

During the course of our research, we came across 22 products currently in different stages of development. We expect around ten products to be launched by the end of this decade, providing the much needed push to this market. Technological advancements will ensure the development of microneedle systems with improved safety and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters.

 

Scope of the Report

The ‘Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030’ report provides an extensive study in the field of microneedle based delivery systems for therapeutic use. The report covers various aspects, such as, benefits of microneedle assisted drug delivery over conventional needle-syringe system, key industry stakeholders, manufacturing challenges and upcoming opportunities.

One of the key objectives of this report is to understand the current and future state of the microneedles market. This is done by analysing

  • Products currently available in the market and those under development (both clinical / pre-clinical)
  • Recent partnerships which have taken place over the last few years covering product co-development and technology licensing
  • Spin-off companies from academic institutions carrying forward the research work to develop end-user products
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2013. The study provides short-mid term and long term market forecasts for the period 2014 - 2022 and 2022 - 2030, respectively. The research, analysis and insights presented in this report include potential sales of microneedle based delivery devices based on the adoption of 13 marketed and pipeline products; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

For the scope of our report, we have only considered the microneedle products intended for medicinal use and excluded the microneedle-based products which are directed towards cosmetic applications. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2  presents an executive summary of the report. It offers a high level view on where the microneedles market is headed in the mid-long term.

Chapter 3  provides a general introduction to microneedles for transdermal drug delivery. In this section we have discussed, in detail, the concept of microneedles, their historical evolution, mechanism of action and advantages over traditional needle syringes.

Chapter 4  provides an overview of the market landscape. This chapter includes comprehensive information on various technology providers, types of microneedle products, associated materials and manufacturing processes. Information regarding the partnerships that have taken place in the past few years has also been included in this chapter.

Chapter 5  focuses on the key technology providers which have proprietary microneedle technology, with special reference to companies which have microneedle based products under clinical stage of development. In addition to providing detailed profiles of five leading players in the industry, we have also looked at 13 other players which are currently focused in this market.

Chapter 6  discusses the notable microneedle based research work currently underway in academia. It includes comprehensive information on various universities, along with their projects, which have taken a keen interest in this emerging research area.

Chapter 7  provides insights on all the products that are currently marketed or being developed based on the microneedle technology. All these drugs / vaccines have been profiled in this chapter. Amongst other things, these profiles include information related to drug specifications, current stage of development, clinical trials details etc.

Chapter 8  includes case studies of two additional products that are based on microneedle technology but employ a different mode of administration. In addition, we have also profiled a contract manufacturer which manufactures microneedle using its proprietary micro molding technology.

Chapter 9  identifies the forecasted future opportunity presented by the microneedle market. It includes our sales estimates on individual products that are currently marketed or are likely to be available in the near future. We have provided three different growth scenarios for the time period 2014 - 2030.

Chapter 10  provides our analysis of the strengths, weaknesses, opportunities and threats influencing the overall market, capturing the key elements likely to determine future growth.

Chapter 11  is a collection of interview transcripts; these discussions have helped us in forming a better understanding of the key market dynamics, competitive landscape and the likely future trends.

Chapter 12  summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 13  is an appendix, which provides tabulated data and numbers for all the figures presented in the report.

Chapter 14  is an appendix, which lists down all the companies and organisations referenced in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION TO MICRONEEDLES
3.1. What are Microneedles?
3.2. Historical Evolution
3.3. Why Transdermal Mode of Drug Administration?
3.4. The Need for Using Microneedles
3.5. Drawbacks of Conventional Needle Based Delivery
3.6. Benefits of Microneedle Based Delivery System
3.7. Types of Microneedles
3.7.1. Solid Microneedles
3.7.2. Hollow Microneedles
3.7.3. Dissolvable Microneedles
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Transdermal Drug Delivery Systems
4.3. Manufacturing
4.3.1. MEMS Technology
4.3.2. Micromilling Technology
4.4. Microneedle Technology Providers
4.5. Recent Partnerships
 
5. TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Becton Dickinson (BD)
5.2.1. Soluvia: Prefillable Microinjection System
5.2.2. Marketing Approvals
5.2.3. Sales Performance
5.2.4. Partnerships
 
5.3. Clearside Biomedical
5.3.1. Microinjector
5.3.1.1. Patents
5.3.1.2. Manufacturing Capability
5.3.2. Product Pipeline
5.3.3. Funding
5.3.4. Partnership
 
5.4. Corium International
5.4.1. MicroCor Technology
5.4.1.1. Delivery Through an Applicator
5.4.1.2. Manufacturing Capability
5.4.2. Product Pipeline
5.4.3. Sales Performance
5.4.4. Partnership
5.4.5. Funding
5.4.6. Future Plans
 
5.5. NanoPass Technologies
5.5.1. MicronJet 600 Needle
5.5.1.1. US and EU Device Approval
5.5.1.2. Manufacturing Capabilities
5.5.2. Product Pipeline
5.5.3. Partnerships
5.5.4. Funding
 
5.6. Zosano Pharma
5.6.1. ZP Patch Technology
5.6.1.1. Applicator Device
5.6.2. Product Pipeline
5.6.3. Funding
5.6.4. Partnerships
5.6.5. Future Plans
 
5.7. Other Technology Providers
5.7.1. 3M Drug Delivery Systems
5.7.1.1. Microneedle Technology
5.7.1.2. Sales Performance
5.7.1.3. Partnerships
 
5.7.2. Apogee Technology
5.7.2.1. PyraDerm
5.7.2.2. Partnership
 
5.7.3. BioSerenTach Inc.
5.7.3.1. Dissolvable Microneedle (DM) Chip
5.7.3.2. Recent Developments
 
5.7.4. Debiotech
5.7.4.1. DebioJect System
5.7.4.2. Clinical Trials
5.7.4.3. Partnerships and Awards
 
5.7.5. FluGen
5.7.5.1. Technology
5.7.5.2. Funding
 
5.7.6. Fujifilm
5.7.6.1. Micro-Needle Array
5.7.6.2. Sales Performance
 
5.7.7. ImmuPatch
5.7.7.1. ImmuPatch Technology
5.7.7.2. Research and Funding
 
5.7.8. Micropoint Technologies
5.7.8.1. Microneedle Technology
5.7.8.2. Funding
 
5.7.9. nanoBioSciences
5.7.9.1. AdminPen Injection System
 
5.7.10. Nemaura Pharma
5.7.10.1. Microneedle Technology
5.7.10.2. Recent Developments
 
5.7.11. TheraJect
5.7.11.1. TheraJect MAT System
5.7.11.2. Research and Funding
 
5.7.12. Valeritas
5.7.12.1. Micro-Trans Microneedle System
5.7.12.2. Funding and Awards
 
5.7.13. Vaxxas
5.7.13.1. Nanopatch
5.7.13.2. Partnership and Funding
 
6. ACADEMIA
6.1. Chapter Overview
6.2. Queen’s University Belfast
6.2.1. Microneedle Technology
6.2.2. Advantages
6.2.3. Awards and Opportunity
 
6.3. Emory and Georgia Technology
6.3.1. Microneedle Technology
6.3.2. Research Programs
6.3.3. Other Developments
 
6.4. North Carolina State University and University of California, San Diego
6.4.1. Research Programs
 
6.5. University of Pittsburgh
6.5.1. Research Programs
 
6.6. University of Washington
6.6.1. Research Programs
 
6.7. Cardiff University
6.7.1. Research Programs
 
7. PRODUCT PROFILES
7.1. Chapter Overview
7.2. Fluzone Intradermal, Sanofi Pasteur
7.2.1. Regulatory Approvals
7.2.2. Pricing
7.2.3. Manufacturing
 
7.3. Intanza, Sanofi Pasteur
7.3.1. Regulatory Approval
7.3.2. Manufacturing
 
7.4. Polio Vaccine, NanoPass Technologies
7.4.1. Increased use of IPV
7.4.2. Microneedle Assisted IPV
7.4.3. Clinical Trials
 
7.5. CLS-1001, Clearside Biomedical
7.5.1. Clinical Trials
7.5.2. Future Plans
 
7.6. Cat-SPIRE, Circassia
7.6.1. ToleroMune Technology
7.6.2. Partnership for Intradermal Delivery
7.6.3. Clinical Trials
7.6.4. Future Plans
 
7.7. Abaloparatide-TD (BA058), Radius Health
7.7.1. Clinical Trials
7.7.2. Manufacturing
7.7.3. Funding and Collaborations
7.7.4. Future Plans
 
7.8. CLS-1003, Clearside Biomedical
7.8.1. Future Plans
 
7.9. Ragweed–SPIRE, Circassia
7.9.1. Clinical Trials
7.9.2. Future Plans
 
7.10. Grass-SPIRE, Circassia
7.10.1. Clinical Trials
7.10.2. Future Plans
 
7.11. ZP-PTH Weekly, Zosano Pharma
7.11.1. Clinical Trials
7.11.2. Future Plans
 
7.12. MicroCor PTH, Corium International
7.12.1. Clinical Trials
7.12.2. Future Plans
 
7.13. HDM-SPIRE, Circassia
7.13.1. Clinical Trials
7.13.2. Future Plans
 
7.14. ZP-Glucagon, Zosano Pharma
7.14.1. Clinical Trials
7.14.2. Future Plans
 
7.15. H5N1 Avian Influenza VLP Vaccine, Medicago
7.15.1. VLP Technology
7.15.2. Intradermal Formulation
7.15.3. Clinical Trials
 
7.16. Products in Preclinical Trials
 
8. CASE STUDIES
8.1. Chapter Overview
8.2. Rapid Infuser and V-Go (Valeritas, Inc.)
8.2.1. Introduction
8.2.2. Rapid Infuser
8.2.2.1. Key Features
8.2.2.2. Advantages
8.2.3. V-Go
8.2.3.1. Key Features
8.2.3.2. Advantages
 
8.3. BD Libertas™ Patch Injector (BD Medical)
8.3.1. Introduction
8.3.2. Product Description
8.3.3. Usage / Mechanism
8.3.4. Advantages
8.3.5. Current Status
 
8.4. Phillips Medisize Corporation
8.4.1. Company Overview
8.4.2. Microneedle Based Drug Delivery
8.4.3. Microneedle Manufacturing
 
9. MARKET FORECAST, 2014-2030
9.1. Chapter Overview
9.2. Scope and Limitations
9.3. Forecast Methodology
9.4. Overall Microneedles Market for Drug Delivery, 2014-2030
9.5. Soluvia (Becton Dickinson)
9.5.1. Soluvia Sales forecast: Short-Mid Term, 2014-2022
9.5.2. Soluvia Sales forecast: Long Term, 2022-2030
9.6. Polio Vaccine (Nanopass Technologies)
9.6.1. Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022
9.6.2. Polio Vaccine Sales Forecast: Long Term, 2022-2030
9.7. CLS-1001 (Clearside Biomedical)
9.7.1. CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022
9.7.2. CLS-1001 Sales Forecast: Long Term, 2022-2030
9.8. Cat-SPIRE (Circassia)
9.8.1. Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.8.2. Cat-SPIRE Sales Forecast: Long Term, 2022-2030
9.9. BA058 (Radius Health)
9.9.1. BA058 Sales Forecast: Short-Mid Term, 2014-2022
9.9.2. BA058 Sales Forecast: Long Term, 2022-2030
9.10. CLS-1003 (Clearside Biomedical)
9.10.1. CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022
9.10.2. CLS-1003 Sales Forecast: Long Term, 2022-2030
9.11. Flu Vaccine Patch (Dr. Prausnitz Group)
9.11.1. Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022
9.11.2. Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030
9.12. Ragweed-SPIRE (Circassia)
9.12.1. Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.12.2. Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030
9.13. Grass-SPIRE (Circassia)
9.13.1. Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.13.2. Grass-SPIRE Sales Forecast: Long Term, 2022-2030
9.14. ZP-PTH Weekly (Zosano Pharma)
9.14.1. ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022
9.14.2. ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030
9.15. MicroCor PTH (Corium International)
9.15.1. MicroCor PTH Sales Forecast: Short-Mid Term, 2014-2022
9.15.2. MicroCor PTH Sales Forecast: Long Term, 2022-2030
9.16. HDM-SPIRE (Circassia)
9.16.1. HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022
9.16.2. HDM-SPIRE Sales Forecast: Long Term, 2022-2030
9.17. ZP-Glucagon (Zosano Pharma)
9.17.1. ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022
9.17.2. ZP-Glucagon Sales Forecast: Long Term, 2022-2030
 
10. SWOT ANALYSIS
10.1. Strengths
10.2. Weakness
10.3. Opportunities
10.4. Threats
 
11. INTERVIEW TRANSCRIPTS
11.1. Interview 1: Nemaura Pharma, Dr. Faz Chowdhury, CEO
11.2. Interview 2: TheraJect, Dr. Sung Yun Kwon, CEO
11.3. Interview 3: North Carolina State University, Dr. Roger Narayan, Professor
11.4. Interview 4: Clearside Biomedical, Steve Lang, VP, Commercial Operations
 
12. CONCLUSION
12.1. Microneedles: Alternative to Hypodermic Injections
12.2. Academia is at the Forefront of Research; Spin-offs will Drive Commercial Applications
12.3. Emerging Market, with A Huge Growth Potential
12.4. Contract Manufacturers Likely to Play an Important Role in Realising the Ambition
12.5. Concluding Remarks
 
13. APPENDIX 1: TABULATED DATA
 
14. APPENDIX 2: LIST OF COMPANIES AND ORGANISATIONS

List of Figures

Figure 3.1 Viral Infection Cases Due to Unsafe Injections (in 000’)
Figure 4.1  Transdermal Products: Distribution by Technology
Figure 4.2  Microneedle Devices: Distribution by Patches and Syringes
Figure 4.3 Microneedle Devices: Distribution by Type of Microneedle
Figure 5.1  BD: Sales, 2013-Q3, 2014 (USD Billion)
Figure 5.2  BD: 2013 Sales by Business Division (USD Billion)
Figure 5.3  BD Medical: 2013 Sales by Product Segment (USD Billion)
Figure 5.4  Corium: Sales Q2-Q3, 2014 (USD Million)
Figure 5.5  3M: Sales, 2009-2013 (USD Billion)
Figure 5.6  Fujifilm: Sales, 2014 (JPY Billion)
Figure 7.1  Distribution of Marketed / Pipeline Products using Microneedle Systems
Figure 9.1  Overall Microneedle Market for Drug Delivery (Million Units), 2014 – 2030
Figure 9.2  Soluvia Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.3  Soluvia Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.4 Polio Vaccine Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.5 Polio Vaccine Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.6 CLS-1001 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.7  CLS-1001 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.8  Cat-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.9  Cat-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.10  BA058 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.11  BA058 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.12 CLS-1003 Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.13  CLS-1003 Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.14  Flu Vaccine Patch Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.15  Flu Vaccine Patch Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.16  Ragweed-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.17  Ragweed-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.18  Grass-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.19  Grass-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.20  ZP-PTH Weekly Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.21  ZP-PTH Weekly Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.22  MicroCor PTH Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.23  MicroCor PTH Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.24  HDM-SPIRE Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.25  HDM-SPIRE Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 9.26  ZP-Glucagon Sales Forecast (Million Units): Short-Mid Term, 2014-2022 (Base Scenario)
Figure 9.27  ZP-Glucagon Sales Forecast (Million Units): Long Term, 2022-2030 (Base Scenario)
Figure 12.1  Overall Microneedles Market for Drug Delivery (Million Units): 2104, 2022 and 2030

List of Tables

Table 4.1  Approved Transdermal Drug Delivery Systems
Table 4.2  Top 30 MEMS Companies, 2012
Table 4.3  Microneedle Based Drug Delivery: Technology Providers
Table 4.4 Microneedle Based Drug Delivery: List of Partnerships
Table 5.1 Other Companies Active in the Field of Microneedles
Table 5.2  Soluvia: Approvals
Table 5.3  Clearside Biomedical: Product Portfolio
Table 5.4  Corium: Product Portfolio
Table 5.5  NanoPass Technologies: Product Portfolio
Table 5.6  Zosano Pharma: Product Portfolio
Table 5.7  AdminPen Pricing
Table 5.8  AdminPatch Array Pricing
Table 6.1  University Research Technologies
Table 7.1  Marketed or Pipeline Drugs/Vaccines using Microneedle Systems
Table 9.1  Microneedle Based Products: Expected Launch Timelines
Table 10.1  SWOT Analysis
Table 13.1  BD: Sales, 2013-Q3, 2014 (USD Billion)
Table 13.2  BD: 2013 Sales by Business Division (USD Billion)
Table 13.3  BD Medical: 2013 Sales by Product Segments (USD Billion)
Table 13.4  Corium: Sales Q2-Q3, 2014 (USD Million)
Table 13.5  3M: Sales, 2009-2013 (USD Billion)
Table 13.6  Fujifilm: Sales, 2014 (JPY Billion)
Table 13.7  Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Base Scenario)
Table 13.8  Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Optimistic Scenario)
Table 13.9  Overall Microneedle Market for Drug Delivery (Million Units), 2014-2030 (Conservative Scenario)
Table 13.10  Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.11  Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.12  Soluvia Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.13  Soluvia Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.14  Soluvia Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.15  Soluvia Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.16  Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.17  Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.18  Polio Vaccine Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.19  Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.20  Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.21  Polio Vaccine Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.22  CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.23  CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.24  CLS-1001 Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.25  CLS-1001 Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.26  CLS-1001 Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.27  CLS-1001 Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.28  Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.29  Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.30  Cat-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.31  Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.32  Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.33  Cat-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.34  Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.35  Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.36  Abaloparatide-TD Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.37  Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.38  Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.39  Abaloparatide-TD Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.40  CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.41  CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.42  CLS-1003 Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.43  CLS-1003 Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.44  CLS-1003 Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.45  CLS-1003 Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.46  Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.47  Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.48  Flu Vaccine Patch Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.49  Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.50  Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.51  Flu Vaccine Patch Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.52  Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.53  Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.54  Ragweed-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.55  Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.56  Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.57  Ragweed-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.58  Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.59  Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.60  Grass-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.61  Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.62  Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.63  Grass-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.64  ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.65  ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.66  ZP-PTH Weekly Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.67  ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.68  ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.69  ZP-PTH Weekly Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.70  MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.71  MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.72  MicroCor-PTH Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.73  MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.74  MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.75  MicroCor-PTH Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.76  HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.77  HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.78  HDM-SPIRE Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.79  HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.80  HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.81  HDM-SPIRE Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)
Table 13.82  ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Base Scenario)
Table 13.83  ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Conservative Scenario)
Table 13.84  ZP-Glucagon Sales Forecast: Short-Mid Term, 2014-2022 (Optimistic Scenario)
Table 13.85  ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Base Scenario)
Table 13.86  ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Conservative Scenario)
Table 13.87  ZP-Glucagon Sales Forecast: Long Term, 2022-2030 (Optimistic Scenario)

List of Companies

The following companies have been mentioned in this report.

  1. 10X Technology
  2. 3M Drug Delivery Systems
  3. 3M Unitek
  4. 4P Therapeutics
  5. AAC
  6. Abingworth
  7. Advanced Technology Ventures
  8. Agate Medical Investments
  9. AKM
  10. AllTranz
  11. Alza Corporation 
  12. Amspar B.V
  13. Analog Devices
  14. Angiomed
  15. Aphelion Capital
  16. Apogee Technology
  17. Asahi Kasei Pharma Corporation (AKP)
  18. AvagoTechnologies
  19. Bausch & Lomb
  20. BB Biotech Ventures
  21. Becton Dickinson
  22. Biacore
  23. Biochemics
  24. BioMed Ventures
  25. BioSerenTach
  26. Biotech Growth N.V
  27. Bosch
  28. Brandon Capital
  29. Brookside Capital
  30. Canon
  31. Capital Royalty L.P
  32. Carrera
  33. CEA-LETI
  34. Cerametal
  35. CHL Medical Partners
  36. Circassia
  37. Clearside Biomedical
  38. Corium International
  39. Curasen
  40. Debiotech
  41. Denso
  42. D-Partners
  43. Elcam Medical
  44. Enterprise Ireland
  45. Essex Woodlands Health Ventures 
  46. Extraject Technologies
  47. F2 Biosciences III, L.P. 
  48. Flir Systems
  49. FluGen
  50. Forma Medical 
  51. Fraunhofer Institute
  52. Freescale Semiconductor
  53. Fujifilm
  54. GE Sensing
  55. Georgia Research Alliance Venture Fund 
  56. GSK
  57. Hatteras Venture Partners 
  58. HBM BioVentures
  59. HBM Partners
  60. HealthCare Ventures
  61. Hewlett Packard
  62. HLM Venture Partners
  63. Honeywell
  64. IBM
  65. ImmuPatch
  66. Infineon Technologies
  67. Invensense
  68. Ipsen Pharma 
  69. Iscar
  70. Israel HealthCare Ventures (IHCV)
  71. Janisys
  72. Janssen Pharmaceuticals
  73. Kaiser Permanente Ventures
  74. Kenan Flagler Business School Private Equity Fund
  75. Kionix
  76. Knowles Electronics
  77. Knox LLC 
  78. Lexmark
  79. Lonza Group Ltd. 
  80. Macroflux Corporation
  81. Measurement Specialities Inc.
  82. Mecaplast
  83. Medicago
  84. Memsic
  85. Mercatus Capital and GITP (Global Innovations & Technology Platform) Investments
  86. Merck
  87. Metalor Dental
  88. MicroCreate B.V 
  89. Micropoint Technologies
  90. Mountain Group Capital
  91. MPM Capital
  92. Murata
  93. MyLife Technologies
  94. nanoBioSciences
  95. Nanopass
  96. Nemaura Pharma
  97. New Enterprise Associates (NEA) 
  98. Nissha Printing Co. Ltd
  99. Nomura Phase4 Ventures
  100. Novartis
  101. Novo Nordisk
  102. Novosanis
  103. Ofer Hi-Tech
  104. Omron
  105. OneVentures
  106. ONSET Ventures
  107. Oxford NanoDelivery
  108. Panasonic
  109. Par Pharmaceuticals
  110. Philips Medisize
  111. Phillips Plastic Corporation
  112. Phonak AG
  113. Pitango Venture Capital
  114. PKA SoftTouch Corp 
  115. Procter & Gamble
  116. Pro-micron
  117. ProQuest Investments
  118. Quantum Technology Partners 
  119. Radius Health
  120. Robert Bosch
  121. Rolex
  122. RusanoMedInvest (RMI)
  123. Sanofi Pasteur
  124. Santen Inc.
  125. Seco
  126. Seiko Epson
  127. Sensata
  128. Sony
  129. ST Microelectronics
  130. Star Surgical
  131. StrataGent Life Sciences
  132. TechnoPhage
  133. Teva Pharmaceuticals
  134. Texas Instruments
  135. TheraJect
  136. TransDerm Inc.
  137. Triquint
  138. Tyco Electronics
  139. Ulis
  140. UTC Aerospace
  141. Valeritas
  142. Vaxxas
  143. Welsh, Carson, Anderson & Stowe (WCAS) 
  144. WFD Ventures 
  145. Zosano Pharma

The following organisations have been mentioned in this report.

  1. Cardiff University
  2. Emory University
  3. European Medicines Agency (EMA)
  4. Food and Drug Administration (FDA)
  5. Georgia Institute of Technology
  6. Georgia Research Alliance
  7. Health Canada
  8. Imperial College, London
  9. Infectious Disease Research Institute (IDRI)
  10. Institute of Materials Research & Engineering
  11. Juvenile Diabetes Research Foundation (JDRF)
  12. Kyoto Pharmaceutical University
  13. National Institutes of Health (NIH)
  14. National Science Foundation
  15. North Carolina State University
  16. Oxford University
  17. PATH
  18. Queen’s University Belfast
  19. Royal Institute of Technology, Stockholm
  20. Shanghai Institute of MateriaMedica (SIMM)
  21. St. Jude Children’s Research Hospital
  22. Technology Strategy Board
  23. Tyndall National Institute
  24. University College Cork (UCC)
  25. University of California
  26. University of Melbourne
  27. University of Pittsburgh
  28. University of Queensland
  29. University of Washington
  30. University of Wisconsin, Madison
  31. Vaccine and Immunotherapy Centre of the Centre Hospitalier Universitaire Vaudois (CHUV)
  32. Vaccine and Infectious Disease Organization (VIDO)
  33. World Health Organization (WHO)

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 1,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com